Naranie Shanmuganathan

20PUBLICATIONS
67CO-AUTHORS
Cancer cell biologyHaematological tumoursRegenerative medicine (incl. stem cells)HaematologyCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (20)

|Jun 11, 2026
Direct measurement of in vivo BCR::ABL1 kinase inhibition reveals stronger potency of asciminib as compared with imatinib and nilotinib.

|Apr 25, 2026
Targeting the BCR::ABL1 Kinase: Advances Beyond Imatinib in Chronic Myeloid Leukemia.

|Sep 16, 2025
Granulocyte abundance and maturation state at diagnosis predicts treatment-free remission in CML.

Mikko Purhonen, Mikael Tatun, Katariina Luukkainen

|Sep 02, 2025
Impact of ASXL1 at diagnosis in patients with CML receiving frontline potent TKIs: high risk of kinase domain mutations.

Naranie Shanmuganathan, David T Yeung, Carol Wadham

|Sep 18, 2024
A critical review of management of allogeneic transplant-eligible adults with Ph+ acute lymphoblastic leukaemia.

Naranie Shanmuganathan, Andrew Grigg

|Aug 05, 2024
Asciminib monotherapy as frontline treatment of chronic-phase chronic myeloid leukemia: results from the ASCEND study.

David T Yeung, Naranie Shanmuganathan, John Reynolds

Pageof 4

Frequent Collaborators

8 joint publications

David Morrall Ross

7 joint publications

Susan Branford

6 joint publications

Timothy P Hughes

4 joint publications

Chung Hoow Kok